-
Acorda Therapeutics Announces Delisting from Nasdaq
15 Apr 2024 21:15 GMT
… “ACORQ” ticker symbol.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function … ) following our loss of patent exclusivity; competition from generic … of FAMPYRA (dalfampridine) following patent challenges in jurisdictions outside …
-
Acorda Therapeutics Announces Nasdaq Delisting Notification
03 Apr 2024 21:42 GMT
… the “pink sheets”).
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function … ) following our loss of patent exclusivity; competition from generic … of FAMPYRA (dalfampridine) following patent challenges in jurisdictions outside …
-
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
01 Apr 2024 22:58 GMT
… and Exchange Commission.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore … ) following our loss of patent exclusivity; competition from generic … of FAMPYRA (dalfampridine) following patent challenges in jurisdictions outside …
-
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
11 Jan 2024 13:27 GMT
… for more information.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function … ) following our loss of patent exclusivity; competition from generic … of FAMPYRA (dalfampridine) following patent challenges in jurisdictions outside …
-
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 21:12 GMT
… at this time.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function … ) following our loss of patent exclusivity; the ability to realize … by law.
Financial Statements
Acorda Therapeutics, Inc.
Condensed Consolidated Balance …
-
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
06 Nov 2023 13:18 GMT
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced … of saliva or spit.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function … (dalfampridine) following our loss of patent exclusivity; the ability to realize …
-
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 20:13 GMT
… at this time.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore … ) following our loss of patent exclusivity; the ability to …
864
1,242
732
Acorda Therapeutics, Inc.
Adjusted Operating Expenses Reconciliation …
-
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
02 Aug 2023 12:19 GMT
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced … Full Prescribing Information here.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function … (dalfampridine) following our loss of patent exclusivity; the ability to realize …
-
Tom Burns Elected to the Acorda Therapeutics Board of Directors
28 Jun 2023 21:25 GMT
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced … from Golden Gate University.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function … (dalfampridine) following our loss of patent exclusivity; the ability to realize …
-
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
26 Jun 2023 12:27 GMT
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced … Nasdaq Global Select Market.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function … (dalfampridine) following our loss of patent exclusivity; the ability to realize …
About
© 1995-2024